References
Helbig G, Koclega A, Gaweł WB et al (2020) The efficacy of cladribine (2-CDA) in advanced systemic mastocytosis. Indian J Hematol Blood Transfus Grzegorz Helbig. https://doi.org/10.1007/s12288-020-01279-8
Gotlib J, Gerds AT, Bose P et al (2018) Systemic mastocytosis, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 16:1500–1537
(2019) https://www.uptodate.com/contents/advanced-systemic-mastocytosis-management-and-prognosis. Accessed July 2020
Pardanani A, Shah S, Mannelli F et al (2018) Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models. Blood Adv 2:2964
Jawhar M, Schwaab J, Álvarez-Twose I et al (2019) MARS: Mutation-adjusted risk score for advanced systemic mastocytosis. J Clin Oncol 37:2846
Funding
None.
Author information
Authors and Affiliations
Contributions
Concept—I.Y., A.T., Design—A.T., I.Y.; Supervision—I.Y..; Resources—I.Y., A.T.; Materials—I.Y., A.T.; Data Collection and/or Processing—A.T., I.Y.,; Analysis and/or Interpretation–I.Y., A.T.; Literature Search—A.T.; Writing Manuscript—A.T.; Critical Review—I.Y., A.T.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Yavaşoğlu, I., Turgutkaya, A. Systemic Mastocytosis: Response to the Efficacy of Cladribine(2-CdA) with Current Terminology and Approach. Indian J Hematol Blood Transfus 37, 329–330 (2021). https://doi.org/10.1007/s12288-020-01332-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-020-01332-6